Press Release FeedGet the RSS feed
Menu

Business Wire

QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel

Business Wire

  • Bloodstream infections can trigger sepsis, a life-threatening response to infection; about 1.7 million U.S. adults develop sepsis each year, contributing to at least 350,000 deaths

  • New QIAstat-Dx test identifies 13 gram-negative bacterial targets and 18 antibiotic resistance markers in about one hour

  • Complete QIAstat-Dx bloodstream infection menu combines two complementary panels and covers 33 pathogen targets and 28 antibiotic resistance markers

GERMANTOWN, Md. & VENLO, Netherlands, September 28, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S. laboratories now have access to the complete QIAstat-Dx bloodstream infection portfolio following clearance of a new panel by the U.S. Food and Drug Administration (FDA).

The new panel detects gram-negative bacteria and antibiotic resistance markers in about one hour, complementing the recently FDA-cleared QIAstat-Dx panel for gram-positive bacteria and fungi.

Bloodstream infections can become serious very quickly and can trigger sepsis, a life-threatening response to infection that can lead to organ failure and death. According to the U.S. Centers for Disease Control and Prevention, about 1.7 million adults in the U.S. develop sepsis each year, and at least 350,000 die during hospitalization or are discharged to hospice. Faster identification of what is causing an infection can provide clinicians with important information to guide treatment decisions.

The new QIAstat-Dx BCID GN Plus AMR Panel identifies 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers. It complements the recently cleared QIAstat-Dx BCID GPF Plus AMR Panel, which identifies gram-positive bacteria and fungi.

Together, the two panels cover 33 pathogen targets and 28 antimicrobial resistance markers. The gram-negative panel covers 13 pathogen targets and 18 resistance markers, while the gram-positive and fungal panel covers 20 pathogen targets and 10 resistance markers. Both deliver results in about one hour.

The clearance also expands the QIAstat-Dx infectious disease testing menu in the U.S., which already includes tests for respiratory and gastrointestinal infections, as well as for meningitis and encephalitis.

"Bloodstream infections demand fast answers," said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. "With both panels now cleared in the U.S., laboratories can identify a broad range of pathogens and antibiotic resistance markers on the same QIAstat-Dx system. This can provide clinicians with timely information to support treatment decisions and address antibiotic resistance."

  1. SaaSThe Prostate Cancer FoundationProstate Cancer Foundation Expands Radiopharmaceutical Think Tank as Field Enters Pivotal Growth Phase– PCF Think Tank aims to increase adoption of radiopharmaceuticals as major oncology therapeutic platform in prostate cancer treatment and to other tumor types – – New members Orano Med, Telix and Siemens Healthineers join PCF and industry leaders at kickoff meeting at 2026 EANM Annual Congress to address key challenges i
  2. FinanceAlign Technology, Inc.Align Technology Wins Significant Patent Infringement Case Against Angelalign at Unified Patent CourtCompanies: Align TechnologySAN JOSE, Calif. & TEMPE, Ariz., October 17, 2026--Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, welcomes the decision of the Unified Patent Court ("UPC") finding that aligner syst
  3. AISyncra and Neumetry Partner to Build AI-Powered Readiness Platform for Teenage Athletes and Their CoachesSmart ring data meets FDA-cleared physiological AI to help coaches see which athletes are ready to compete, and which need rest LAS VEGAS & SAN JOSE, Calif., October 17, 2026--Syncra Labs Inc., maker of the Syncra smart ring, and Neumetry Medical, Inc., developer of an FDA-cleared predictive health pla
  4. HealthcareAIDS Healthcare FoundationAHF Commemorates 40 Years of Global Impact During Annual World AIDS Day Concert Celebration Featuring Ricky MartinLOS ANGELES, October 16, 2026--AIDS Healthcare Foundation (AHF) , the world's largest, non-profit public health organization providing direct HIV/ADS services to over 3.3 million clients across the globe, will celebrate 40 years of impact during its annual World AIDS Day concert commemoration. Continu
  5. Real estateKBRA Assigns Preliminary Ratings to Angel Oak Mortgage Trust 2026-6 (AOMT 2026-6)NEW YORK, October 16, 2026--KBRA assigns preliminary ratings to ten classes of mortgage-backed certificates from Angel Oak Mortgage Trust 2026-6 (AOMT 2026-6), a $250.6 million non-prime RMBS transaction. The underlying collateral, comprised of 381 residential mortgages, and includes a meaningful conce
  6. FinanceUL SolutionsUL Solutions Warns of GFCI and Duplex Wall Outlets Modified by Third Parties to Include Built-in CamerasAfter manufacturing, third parties added built-in cameras to the wall outlets; UL Solutions did not evaluate the modified products and recommends that they be immediately removed from service and discarded. NORTHBROOK, Ill., October 16, 2026--UL Solutions (NYSE: ULS), a global leader in applied safety